# Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

> **NCT04882293** · PHASE3 · UNKNOWN · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 78 (estimated)

## Conditions studied

- Dyslipidemia Associated With Type II Diabetes Mellitus

## Interventions

- **DRUG:** Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose
- **DRUG:** Atorvastatin (Lipitor ®)

## Key facts

- **NCT ID:** NCT04882293
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-15
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882293, "Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04882293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*